Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Retained Earnings: 2009-2024

Historic Retained Earnings for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to -$1.4 billion.

  • Northwest Biotherapeutics' Retained Earnings fell 6.34% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 6.34%. This contributed to the annual value of -$1.4 billion for FY2024, which is 6.16% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Retained Earnings of -$1.4 billion as of FY2024, which was down 6.16% from -$1.4 billion recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' Retained Earnings ranged from a high of -$1.2 billion in FY2021 and a low of -$1.4 billion during FY2024.
  • Over the past 3 years, Northwest Biotherapeutics' median Retained Earnings value was -$1.4 billion (recorded in 2023), while the average stood at -$1.4 billion.
  • Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 62.97% in 2020, then increased by 13.06% in 2021.
  • Over the past 5 years, Northwest Biotherapeutics' Retained Earnings (Yearly) stood at -$1.4 billion in 2020, then rose by 13.06% to -$1.2 billion in 2021, then dropped by 8.81% to -$1.3 billion in 2022, then fell by 4.83% to -$1.4 billion in 2023, then declined by 6.16% to -$1.4 billion in 2024.